Vascular reactivity in obstructive sleep apnea syndrome

American Journal of Respiratory and Critical Care Medicine

Volumn 161, Issue 1, 2000, Pages 187-191

  Duchna, Hans W ^a,b   Guilleminault, Christian ^a,b   Stoohs, Riccardo A ^a,b   Faul, John L ^a,b   Moreno, Heitor ^a,b   Hoffman, Brian B ^a,b   Blaschke, Terence F ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; GLYCERYL TRINITRATE; PHENYLEPHRINE; VASOACTIVE AGENT;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; HUMAN; HYPERTENSION; MALE; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; SLEEP APNEA SYNDROME; VEIN COMPLIANCE; VEIN DILATATION; VENOUS RETURN;

EID: 0033977184     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.161.1.9810062     Document Type: Article

References (31)

1. 1. Young, T., M. Palta, J. Dempsey, J. Skatrud, S. Weber, and S. Badr. 1993. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 328:1230-1235.
2. 2. Partinen, M., and C. Guilleminault. 1990. Daytime sleepiness and vascular morbidity at seven-year follow-up in obstructive sleep apnea. Chest 97:27-32.
3. 3. He, J., M. H. Kryger, F. J. Zorick, W. Conway, and T. Roth. 1988. Mortality and apnea index in obstructive sleep apnea. Chest 94:9-14.
4. 4. Guilleminault, C., S. J. Connolly, and R. A. Winkle. 1983. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am. J. Cardiol. 52:49-54.
5. 5. Fletcher, E. C. 1995. The relationship between systemic hypertension and obstructive sleep apnea: facts and theory. Am. J. Med. 98:118-128.
6. 6. Fletcher, E. C. 1986. Abnormalities of Respiration During Sleep. Grune and Stratton, Orlando, FL.
7. 7. Stoohs, R., and C. Guilleminault. 1992. Cardiovascular changes associated with obstructive sleep apnea syndrome. J Appl. Physiol. 72:583-589.
8. 8. Salejee, I., A. Tarasiuk, I. Reder, and S. M. Scharf. 1993. Upper airway obstruction produces right but not left ventricular hypertrophy in the rat. Am. Rev. Respir. Dis. 148:1346-1350.
9. 9. Palmer, R. M. J., D. S. Ashton, and S. Moncada. 1988. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666.
10. 10. Murad, F. 1986. Cyclic guanosine monophosphate as a mediator of vasodilation. J. Clin. Invest. 78:1-5.
11. 11. Ignarro, L. J., and P. J. Kadowtiz. 1985. The pharmacological and physiological role of cGMP in vascular smooth muscle relaxation. Ann. Rev. Pharmacol. Toxicol. 25:171-191.
12. 12. Aellig, W. H. 1994. Clinical pharmacology, physiology and pathophysiology of superficial veins. Br. J. Clin. Pharmacol. 38:181-196, 289-305.
13. 13. Aellig, W. H. 1981. A new technique for recording compliance of human hand veins. Br. J. Clin. Pharmacol. 11:237-243.
14. 14. Johns, M. W. 1991. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14:540-545.
15. 15. Calver, H., J. Collier, and P. Vallance. 1992. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin. Invest. 90:2548-2554.
16. 16. Rees, D. D., R. M. J. Palmer, and S. Moncada. 1989. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl. Acad. Sci. U.S.A. 86:375-378.
17. 17. Panza, J. A., A. A. Quyyumi, J. R. Brush, and S. E. Epstein. 1990. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 323:22-27.
18. 18. Griffith, T. M., T. H. Edwards, R. L. Davies, T. J. Harrison, and K. T. Evans. 1987. EDRF coordinates the behaviour of vascular resistance vessels. Nature 329:442-445.
19. 19. Pohl, U., L. Dezsi, B. Simon, and R. Busse. 1987. Selective inhibition of endothelium-dependent dilation in resistance-sized vessels in vivo. Am. J. Physiol. 253:234-239.
20. 20. Vallance, P., J. Collier, and S. Moncada. 1989. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2: 997-1000.
21. 21. Vincent, J., T. F. Blaschke, and B. B. Hoffman. 1992. Vascular reactivity to phenylephrine and angiotensin: II. Comparison of direct venous and systemic vascular responses. Clin. Pharmacol. Ther. 51:68-75.
22. 22. Sajkov, D., T. Wandg, N. A. Saunders, A. J. Bune, A. M. Neill, and R. Douglas McEvoy. 1999. Daytime pulmonary hemodynamics in patients with obstructive sleep apnea without lung disease. Am. J. Respir. Crit. Care Med. 159:1518-1526.
23. 23. Carlson, J. T., C. Rangemark, and J. A. Hedner. 1996. Attenuated endothelium-dependent vascular relaxation in patients with sleep apnea. J. Hypertension 14:577-584.
24. 24. Hedner, J. A., I. Wilcox, L. Laks, R. R. Grunstein, and C. E. Sullivan. 1992. A specific and potent pressor effect of hypoxia in patients with sleep apnea. Am. Rev. Respir. Dis. 146:1240-1245.
25. 25. Hardy, J. C., K. Gray, S. Whisler, and U. Leuenberger. 1994. Sympathetic and blood pressure responses to voluntary apnea are augmented by hypoxemia. J. Appl. Physiol. 77:2360-2365.
26. 26. Dean, R. T., and I. Wilcox. 1993. Possible atherogenic effects of hypoxia during obstructive sleep apnea. Sleep 16:S15-S22.
27. 27. Ringler, J., R. C. Basner, R. Shannon, R. Schwartzstein, H. Manning, S. E. Weinberger, and J. W. Weiss. 1990. Hypoxemia alone does not explain blood pressure elevations after obstructive apneas. J. Appl. Physiol. 69:2143-2148.
28. 28. Guilleminault, C., R. Stoohs, T. Shiomi, C. Kushida, and I. Schnittger. 1996. Upper airway resistance syndrome, nocturnal blood pressure monitoring, and borderline hypertension. Chest 109:901-908.
29. 29. Waravdekar, N. V., L. I. Sinoway, C. W. Zwillich, and U. A. Leuenberger. 1996. Influence of treatment on muscle sympathetic nerve activity in sleep apnea. Am. J. Respir. Crit. Care Med. 153:1333-1338.
30. 30. Jennum, P., G. Wildschiodtz, N. J. Christensen, and T. Schwartz. 1989. Blood pressure, catecholamines, and pancreatic polypeptide in obstructive sleep apnea with and without nasal continuous positive airway pressure (nasal CPAP) treatment. Am. J. Hyperten. 2:847-852.
31. 31. Hedner, J., B. Darp. H. Ejnell, J. Carlson, and K. Caidahl. 1995. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoėa: cardiovascular implications. Eur. Respir. J. 8:222-229.